Loree Larratt

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Carol Moreno, Richard Greil, Fatih Demırkan et al. · The Lancet Oncology · 2018 · 548 citations

Medicine, Oncology, Pharmacology +13

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

Tadeusz Robak, Anna Dmoszyńska, Philippe Solal‐Céligny et al. · Journal of Clinical Oncology · 2010 · 475 citations · Full text

Medicine, Immunology, Oncology +16

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression

Jonathan J. Keats, Tony Reiman, Christopher A. Maxwell et al. · Blood · 2003 · 384 citations

Medicine, Hematology, Oncology +7

Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Susan O’Brien, Joseph O. Moore, Thomas E. Boyd et al. · Journal of Clinical Oncology · 2007 · 298 citations

Medicine, Oncology, Pharmacology +15

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Michael R. Grever, Omar Abdel‐Wahab, Leslie A. Andritsos et al. · Blood · 2016 · 289 citations · Full text

Medicine, Hematology, Oncology +10